07-Dec-15 The Chinese medical device market is maturing rapidly, and with it, so is its regulatory presence. Top trends on the horizon for 2016: A move toward localization; research use only loophole closing; imported refurbished products will be a no-no; local bidding for local products; more inspection on the way. [image: MD+DI]

09-Dec-15 Sanofi Pasteur has announced that the Mexican authorities have granted marketing authorization to Dengvaxia®, making it the first vaccine to be licensed in the world for the prevention of dengue. [image: See And Say]

01-Dec-15 When in May-15 Prime Minister Dmitry Medvedev tasked the government with creating a program of pharmaceutical import substitution, foreign companies were worried. Today, 60% of the drugs approved by the Russian government are produced domestically. Under the new policy, this share should increase to 90% by 2018. [image: Getty Images]

16-Nov-15 Japan, with sales of USD115, accounts for 10% of the global pharma market, compared with 38% for the US and 21% for Europe. Lupin is the only Indian company in Japan's generics market. But now Sun Pharmaceuticals is planning to acquire Novartis' Japanese drug portfolio. Other Indian generics makers, including Dr Reddy’s and Glenmark, are also exploring options. [image: Bloomberg]

06-Nov-15 Korea's Hanmi Pharmaceutical has signed a contract with Sanofi to export USD4 bn worth of diabetes treatment technology, in a deal worth almost 30% of the value of the entire Korean pharma industry. Sanofi gains an exclusive worldwide license to develop and commercialize drugs based on the materials, except in Korea and China, where Hanmi retains co-commercialization rights. [image: Business Korea]